Efficacy of Vibegron and Mirabegron for Overactive Bladder: A Systematic Literature Review and Indirect Treatment Comparison.

ABSTRACT:

Background

In the absence of head-to-head trials, we performed an indirect treatment comparison of the β₃-adrenergic agonists vibegron and mirabegron in the treatment of overactive bladder (OAB).

Methods

PubMed, Embase, and Cochrane Library were searched for articles related to phase 3, double-blind, controlled trials of vibegron 75 mg and mirabegron 25/50 mg in patients with OAB. Efficacy outcomes included change from baseline at weeks 4, 12, and 52 in mean daily number of total urinary incontinence episodes and micturitions and mean volume voided/micturition. Effect size was computed as placebo-subtracted change from baseline (weeks 4, 12) or active control (tolterodine)-subtracted change from baseline (week 52) for each treatment group. Adverse events (AEs) are

SUBMITTER: Kennelly MJ 

PROVIDER: S-EPMC8520873 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature